MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WOYNAROWSKI, J. M.
Right arrow Articles by BEERMAN, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WOYNAROWSKI, J. M.
Right arrow Articles by BEERMAN, T. A.

Molecular Pharmacology, Vol 18, 491-496, Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics

Inhibition of DNA Replication in HeLa S3 Cells by Macromomycin-I, an Antitumor Protein Antibiotic

JAN M. WOYNAROWSKI 1 and TERRY A. BEERMAN 1

1 Department of Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York 14263

Macromomycin-I, a chromophore-containing form of an antitumor protein antibiotic macromomycin, was found to be a potent inhibitor of [3H]thymidine incorporation into DNA in intact nonsynchronous and G1/S-synchronized HeLa S3 cells. This inhibitory effect depended on the drug dose and duration of treatment, but was essentially independent of the cell cycle position, within the G1 through S phases. A parallel inhibition of DNA synthesis was observed in lysates and purified nuclei from drug-treated cells (as measured by incorporation of radioactive dTTP into DNA), indicating that the drug interferes with DNA biosynthesis after formation of deoxynucleoside triphosphates. The addition of a cytoplasmic fraction from untreated cells to purified nuclei from drug-treated cells failed to overcome the inhibition of DNA synthesis, while a cytoplasmic fraction from drug-treated cells was able to stimulate efficiently DNA synthesis in purified nuclei from untreated cells. Moreover, the inhibition of DNA synthesis in nuclei from drug-treated cells could be overcome by the addition of exogeneous DNA. These data demonstrate that macromomycin-I acts on DNA replication by interfering with the template and probably does not affect DNA polymerase or other factors involved in replication. In addition, macromomycin-I was found to enhance the incorporation of [3H]thymidine into DNA in HeLa S3 cells in the presence of hydroxyurea; thus, the drug seems to stimulate DNA repair. Both findings, inhibition of DNA replication and stimulation of repair synthesis, probably arise from the drug’s damage to DNA and support the assumption that this damage is a primary event in the cytotoxic action of macromomycin.

Note:
ACKNOWLEDGMENTS The authors would like to thank Jeffrey LaDuca for his excellent technical assistance and Nina Ruth Wright for her aid in editing the manuscript.

Submitted on December 26, 1979
Accepted on July 7, 1980







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics